BRISBANE, Calif. / Apr 10, 2023 / Business Wire / Cutera, Inc. (Nasdaq: CUTR) (“Cutera” or the “Company”), a leading provider of aesthetic and dermatology solutions, announced today that it received a notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) that based on the Company’s April 7, 2023 filing of its Form 10-K for the period ended December 31, 2022 (“Form 10-K”), Nasdaq has determined that the Company is now in compliance with the periodic filing requirement of Nasdaq Listing Rule 5250(c)(1). As previously announced, the Company received a notification letter from the Nasdaq that it was not in compliance with Nasdaq Listing Rule 5250(c)(1) due to the delayed filing of its Form 10-K. The Company is now in compliance with all Nasdaq Listing Rules.
The Company’s Form 10-K did not include any restatements of previously issued financial statements. No additional material weaknesses in the Company’s internal control over financial reporting were disclosed in the Form 10-K beyond those previously disclosed by the Company in the amended Form 12b-25 filed by the Company on March 16, 2023.
About Cutera, Inc.
Brisbane, California-based Cutera is a leading provider of aesthetic and dermatology solutions for practitioners worldwide. Since 1998, Cutera has been developing innovative, easy-to-use products that harness the power of science and nature to enable medical practitioners to offer safe and effective treatments to their patients. For more information, call +1-415-657-5500 or 1-888-4CUTERA or visit www.cutera.com.
Last Trade: | US$0.38 |
Daily Change: | 0.02 6.83 |
Daily Volume: | 41,608 |
Market Cap: | US$7.610M |
November 07, 2024 August 08, 2024 July 31, 2024 June 07, 2024 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB